Committed to transforming EEG.

We founded CortiCare as a tele-EEG diagnostic company with a simple premise: to help clinicians determine real-brain functionality and abnormality in a timely and cost-effective manner. Along the way, we've helped redefine remote EEG monitoring in ciritical care and the EMU, expanded the use of in-home ambulatory EEG and provided support for clinical trials.

CortiCare is awarded a portion of the NEOLEV2 drug dosage study awarded to UCSD to monitor up to 300 patients at 5 different hospitals over 3 years.
CortiCare monitors its first patient with just a handful of technologists, and quickly expanded to 10 hospitals served.
CortiCare grows to more than 30 technologists, averaging 10+ years of experience, many who have earned their CLTM.
CortiCare hires its first team of neurophysiologists to provide expert reading services and retains its first contract for reading with a teaching hospital. CortiCare begins monitoring in its first EMU (Epilepsy Monitoring Unit).
CortiCare partners with several well-known institutions, including UCLA and Emory, to provide EEG reading to multiple hospitals nationwide.
CortiCare hires an EU manager and provides EEG monitoring to its first dog in the UK. CortiCare grows to nearly 40 technologists.
CortiCare awarded a pilot program by the Minister of Health for Hospital Affairs in Saudi Arabia to demonstrate effectiveness of ICU brain monitoring services. As a result of this successful pilot, CortiCare is now in negotiations with one of the largest hospitals in Riyadh, Saudi Arabia to provide our real-time brain monitoring services.
CortiCare expands its services to provide remotely monitored, in-home ambulatory video-EEG studies with the acquisition of Physicians Ancillary Services with operations in of the US and a focus on providing the best service in the industry. CortiCare continues to grow its Pharma Clinical Trials services, working with sponsors or CROs to deliver safety EEG monitoring and interpretation.
CortiCare responds to the challenges created by the COVID-19 pandemic with expanded services to hospitals and physicians’ clinics. Our sales team has grown to 10 persons covering all regions of the United States.
CortiCare is awarded Ambulatory Care Accreditation by The Joint Commission, recognizing its commitment to quality patient care. The CortiCare team grows to more than 200 persons, providing market leading service including staffing for in-hospital EEG setup and recording services. In September, CortiCare released and markets the innovative CortiCap disposable EEG electrode cap, making it easier to initiate EEG studies by any healthcare staff member.



Chief Executive Officer

David Roe is a growth-driven healthcare executive with more than 20 years of experience growing firms in the private, publicly traded, and not-for-profit sectors across multiple services, creating partnerships with C-suites, operations, and clinical areas to address and resolve strains presented by the continually evolving healthcare landscape.

Senior Vice-President, Finance

Mr. Weatherwax has a 25-year career in healthcare services with roles including corporate finance and operational management. He led the corporate development efforts at a behavioral health provider and co-founded a boutique healthcare private equity company and held executive roles for healthcare staffing and home healthcare providers.

Senior Vice-President of Operations

Previous Operations Manager for Nuehealth, patient relationship SAAS connecting patients with providers. Previous customer service manager at Alpine Biomed, neuro-based diagnostic products.

Director, Human Resources

With over 15 years of Human Resources experience, Krista has worked in various capacities as an HR Business Partner and HR Manager. She is dedicated to ensuring employees feel heard while creating programs and strategies that align with the goals of the business. As Director of Human Resources, Krista oversees all of the HR functions, including recruiting, benefits, and employee engagement.

Vice-President of Finance

Over 25 years of experience in Finance, Operations, and Business Development. Previously managed several start-up operations in the U.S. and overseas and also owned or served as CFO / Controller for several companies in the service industry.

Director Clinical Trial Services

Jeff has over 35 years’ experience in product management, project management, marketing, and sales, in cardiopulmonary and neurology focused capital equipment and services businesses. He administers the services team for clinical trials and has an in-depth understanding of neurodiagnostic procedures (EEG, PSG, ERP) and how they apply to CNS related pharma clinical trials.

Director of Clinical Operations

Former Senior Manager at several neurodiagnostic services companies, with experience managing a diverse and remotely located operations team.  He has previously held served as the Infection Control Officer and successfully navigated a team to achieve accreditation by The Joint Commission.

Medical Director

Dr. Anderson obtained both his M.D. and Ph.D. at the University of Nebraska Medical Center. He completed his fellowship in clinical neurophysiology with a sub specialization in epilepsy at Emory University. He is widely licensed and credentialed and currently practices telemedicine in 25 states and over 80 hospitals.

Director of Clinical Quality Assurance

With 20 years’ experience in neurodiagnostics, she is the former Chief Technologist at Massachusetts General Hospital.  She serves as Adjunct Faculty in the Neurodiagnostic Technology program at Labouré College and is the current chairperson of the Research Committee for ASET- the Neurodiagnostic Society.

Board of Directors

Chief Executive Officer

David Roe is a growth-driven healthcare executive with more than 20 years of experience growing firms in the private, publicly traded, and not-for-profit sectors across multiple services, creating partnerships with C-suites, operations, and clinical areas to address and resolve strains presented by the continually evolving healthcare landscape.

Corporate Board Member

Principal with 1315 Capital. Ian Li joined 1315 Capital in 2015 and is a Principal on the investment team. Prior to investing, Ian was a healthcare management and strategy consultant at Capgemini Consulting. Ian has worked with commercial executives from top pharmaceutical companies on implementing large scale strategic initiatives, with projects spanning market access, product launch, healthcare reform readiness, and engagement of integrated health network (IHN) customers. Prior to consulting, Ian also had experience working at Stryker Orthopaedics in the quality engineering department. He currently serves on the board of 3B Scientific, CortiCare, and miraDry. Ian also serves as Co-Chair of the Duke University Philadelphia Alumni Board, is on the board of Philadelphia’s Magic Gardens, and is on the leadership team of Out Investors. Ian received a BSE in Biomedical Engineering from Duke University, with a minor in Economics.

Chairman of the Board

Scott Cramer is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Scott has over 35 years’ experience and is a proven and focused medical device, diagnostics and consumer products CEO. He has significant experience driving change by instilling a culture of high performance and implementing growth strategies as well as operational improvement initiatives, resulting in a track-record of successful exits. Most recently Scott was CEO of DNA Diagnostics Center which was a world leader in paternity and relationship testing. The company was acquired by Eurofins in August 2021. Scott currently serves on the board of Biocoat, CortiCare, and Harmac Medical Products. Scott served as Executive Chairman of NeuWave Medical, and has also previously served on the BOD of DDC, Accriva, Veran Medical (acquired by Olympus), Vascular Insights (acquired by Merit Medical), AccuVein, Novasys and Bacchus. He holds a B.S. degree in Finance from Philadelphia University.